Skip to main content
  • Home
  • Making Gains in HFpEF: An Appraisal of Where We Are Now

Making Gains in HFpEF: An Appraisal of Where We Are Now

Topic:
  • Heart Failure

Course Published On:

Course Expiry Date:

Overview

In this symposium, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with a left ventricular ejection fraction >40%. In addition to hearing about the data which led to changes in the recent ACC guidelines, we’ll also explore the impact of clinical inertia and the remaining challenges in HFpEF management.

 

This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.

Commercial Support

This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. The scientific programme has not been influenced in any way by the sponsors.

 

It is not intended for US or UK based healthcare professionals.

Target Audience

This programme is intended to educate:

 

  • Heart Failure Specialists
  • General Cardiologists
  • General Practitioners (GPs)
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Learning Objectives

Upon participation in this programme physicians should be able to:

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
Register now Log in

Module

Title

Duration

Speakers

Presentation & Discussion Patient Case: Typical Patient with HFpEF 15 mins Shelley Zieroth (Manitoba, CA)
Presentation & Discussion SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell 15 mins Javed Butler (Texas, US)
Presentation & Discussion Early Initiation of Foundational Therapy in HF: Why The Urgency? 15 mins Carolyn Lam (Singapore, SG)
Presentation & Discussion.

Patient Case: Typical Patient with HFpEF

Duration: 15 mins

Speakers: Shelley Zieroth (Manitoba, CA)

Presentation & Discussion.

SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell

Duration: 15 mins

Speakers: Javed Butler (Texas, US)

Presentation & Discussion.

Early Initiation of Foundational Therapy in HF: Why The Urgency?

Duration: 15 mins

Speakers: Carolyn Lam (Singapore, SG)

Chair

Shelley Zieroth

Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, CA

Dr Shelley Zieroth is currently at SBH Heart Failure and Transplant Clinics and serves as Head of the Medical Heart Failure Program, WRHA Cardiac Sciences Program, and as Associate Professor of the Section of Cardiology at the University of Manitoba, Canada.

View full profile

Panelist

Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore, SG

Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction.

View full profile

Javed Butler

University of Mississippi Medical Center, US

Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US.

View full profile

N/A

Related Courses

Changing Paradigms in Therapy to Unmet Needs
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response 
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy 
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF 
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice 
See more
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Heart Failure Management in a Changing Paradigm
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Learning objectives

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
See more
HFO 2022 - Session 3.3: Live Case & Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.5 Practical Theory & Hot Topics: Advanced HF Care
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.3 Practical Theory & Hot Topics: HF Aetiology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.2 Live Case and Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more